Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis.

Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA.

Clin Cancer Res. 2019 Jan 1;25(1):125-133. doi: 10.1158/1078-0432.CCR-18-1984. Epub 2018 Oct 9.

PMID:
30301825
2.

Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth.

Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM.

J Med Chem. 2017 Aug 10;60(15):6587-6597. doi: 10.1021/acs.jmedchem.7b00298. Epub 2017 Jul 25.

PMID:
28605593
3.

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.

Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U.

Ann Oncol. 2017 Aug 1;28(8):1869-1875. doi: 10.1093/annonc/mdx207.

PMID:
28460000
4.

GPR56 contributes to the development of acute myeloid leukemia in mice.

Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Hollnagel M, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C.

Leukemia. 2016 Aug;30(8):1734-41. doi: 10.1038/leu.2016.76. Epub 2016 Apr 11.

PMID:
27063597
5.

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.

Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, Tran B, Desai J, Jones I, Croxford M, Jover R, Goel A, Waring P, Hu S, Teichgraber V, Rohr UP, Ridder R, Shanmugam K, Gibbs P.

Clin Cancer Res. 2016 Jul 15;22(14):3488-98. doi: 10.1158/1078-0432.CCR-15-2290. Epub 2016 Mar 30.

6.

Arabinogalactan:β-glucan as novel biodegradable carriers for recombinant human thrombin.

Veverka M, Murányi A, Bakoš D, Kochan J, Jorík V, Omastová M.

J Biomater Sci Polym Ed. 2016;27(3):202-17. doi: 10.1080/09205063.2015.1116886. Epub 2015 Dec 28.

PMID:
26708010
7.

MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.

Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F.

Exp Hematol. 2015 Oct;43(10):858-868.e7. doi: 10.1016/j.exphem.2015.05.018. Epub 2015 Jul 8.

8.

Hemostatic effect and distribution of new rhThrombin formulations in rats.

Kochan J, Schmidtová L, Sadloňová I, Murányi A, Zigová J, Múčková M.

Interdiscip Toxicol. 2014 Dec;7(4):219-22. doi: 10.2478/intox-2014-0032. Epub 2015 Mar 4.

9.

Characterization of thermal properties of municipal solid waste landfills.

Faitli J, Magyar T, Erdélyi A, Murányi A.

Waste Manag. 2015 Feb;36:213-21. doi: 10.1016/j.wasman.2014.10.028. Epub 2014 Nov 17.

PMID:
25464944
10.

[Lyophilisation of protein-based drugs].

Murányi A, Vitková M.

Ceska Slov Farm. 2014 Oct;63(5):199-205. Review. Czech.

PMID:
25354739
11.

Development of gel-forming lyophilized formulation with recombinant human thrombin.

Murányi A, Bartoš P, Tichý E, Lazová J, Pšenková J, Žabka M.

Drug Dev Ind Pharm. 2015;41(9):1566-73. doi: 10.3109/03639045.2014.972411. Epub 2015 Jul 14.

PMID:
25347143
12.

BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt LM, Chan WC, Steidl C, Grogan TM, Rimsza LM.

Hum Pathol. 2014 Oct;45(10):2144-53. doi: 10.1016/j.humpath.2014.06.005. Epub 2014 Jun 26.

13.

GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis.

Lopez-Sanchez I, Dunkel Y, Roh YS, Mittal Y, De Minicis S, Muranyi A, Singh S, Shanmugam K, Aroonsakool N, Murray F, Ho SB, Seki E, Brenner DA, Ghosh P.

Nat Commun. 2014 Jul 21;5:4451. doi: 10.1038/ncomms5451.

14.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J.

Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27.

15.

Commercially available blood-group antibodies may be used to visualize blood group A antigen in paraffin-embedded tissue sections.

Gehrie E, Muranyi A, Walk E, Young PP.

Arch Pathol Lab Med. 2014 Feb;138(2):155. doi: 10.5858/arpa.2013-0302-LE. No abstract available.

PMID:
24476512
16.

Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.

Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q.

Cancer. 2013 Aug 1;119(15):2765-70. doi: 10.1002/cncr.28133. Epub 2013 May 8.

17.

Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.

Argiropoulos B, Yung E, Xiang P, Lo CY, Kuchenbauer F, Palmqvist L, Reindl C, Heuser M, Sekulovic S, Rosten P, Muranyi A, Goh SL, Featherstone M, Humphries RK.

Blood. 2010 May 20;115(20):4071-82. doi: 10.1182/blood-2009-06-225573. Epub 2010 Mar 17.

18.

Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.

Muranyi AL, Dedhar S, Hogge DE.

Leuk Res. 2010 Oct;34(10):1358-65. doi: 10.1016/j.leukres.2010.01.006. Epub 2010 Mar 2.

PMID:
20193963
19.

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A.

Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.

PMID:
19898489
20.

Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.

Muranyi AL, Dedhar S, Hogge DE.

Exp Hematol. 2009 Apr;37(4):450-60. doi: 10.1016/j.exphem.2009.01.002.

PMID:
19302919
21.

MYPT1, the targeting subunit of smooth-muscle myosin phosphatase, is a substrate for the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH).

Webb JD, Murányi A, Pugh CW, Ratcliffe PJ, Coleman ML.

Biochem J. 2009 May 13;420(2):327-33. doi: 10.1042/BJ20081905.

PMID:
19245366
22.

Development of an innovative soil remediation: "Cyclodextrin-enhanced combined technology".

Leitgib L, Gruiz K, Fenyvesi E, Balogh G, Murányi A.

Sci Total Environ. 2008 Mar 15;392(1):12-21. Epub 2007 Dec 21.

PMID:
18082247
23.

Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: inhibitory effects and occurrence in A7r5 cells.

Murányi A, Derkach D, Erdodi F, Kiss A, Ito M, Hartshorne DJ.

FEBS Lett. 2005 Dec 5;579(29):6611-5. Epub 2005 Nov 9.

24.

Localization of myosin phosphatase target subunit and its mutants.

Wu Y, Murányi A, Erdodi F, Hartshorne DJ.

J Muscle Res Cell Motil. 2005;26(2-3):123-34. Epub 2005 Jul 1.

PMID:
15999227
25.

Solution structure of the Ca2+-Binding EGF3-4 pair from vitamin K-dependent protein S: identification of an unusual fold in EGF3.

Drakenberg T, Ghasriani H, Thulin E, Thämlitz AM, Muranyi A, Annila A, Stenflo J.

Biochemistry. 2005 Jun 21;44(24):8782-9.

PMID:
15952784
26.

Laser-doppler examination shows high flow in some common telangiectasias of the lower limb.

Bihari I, Muranyi A, Bihari P.

Dermatol Surg. 2005 Apr;31(4):388-90.

PMID:
15871311
27.

Structural and functional properties of the human notch-1 ligand binding region.

Hambleton S, Valeyev NV, Muranyi A, Knott V, Werner JM, McMichael AJ, Handford PA, Downing AK.

Structure. 2004 Dec;12(12):2173-83.

28.

1H, 13C, and 15N resonance assignments of human Notch-1 calcium binding EGF domains 11-13.

Muranyi A, Hambleton S, Knott V, McMichael A, Handford PA, Downing AK.

J Biomol NMR. 2004 Jul;29(3):443-4. No abstract available.

PMID:
15213460
29.

Myosin phosphatase and myosin phosphorylation in differentiating C2C12 cells.

Wu Y, Erdodi F, Murányi A, Nullmeyer KD, Lynch RM, Hartshorne DJ.

J Muscle Res Cell Motil. 2003;24(8):499-511.

PMID:
14870965
30.

Effect of randomly methylated beta-cyclodextrin on physical properties of soils.

Jozefaciuk G, Muranyi A, Fenyvesi E.

Environ Sci Technol. 2003 Jul 1;37(13):3012-7.

PMID:
12875408
31.

Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase.

Murányi A, MacDonald JA, Deng JT, Wilson DP, Haystead TA, Walsh MP, Erdodi F, Kiss E, Wu Y, Hartshorne DJ.

Biochem J. 2002 Aug 15;366(Pt 1):211-6.

32.

Smooth muscle myosin phosphatase-associated kinase induces Ca2+ sensitization via myosin phosphatase inhibition.

Borman MA, MacDonald JA, Murányi A, Hartshorne DJ, Haystead TA.

J Biol Chem. 2002 Jun 28;277(26):23441-6. Epub 2002 Apr 25.

33.

Integrin-linked kinase phosphorylates the myosin phosphatase target subunit at the inhibitory site in platelet cytoskeleton.

Kiss E, Murányi A, Csortos C, Gergely P, Ito M, Hartshorne DJ, Erdodi F.

Biochem J. 2002 Jul 1;365(Pt 1):79-87.

34.

Effect of cyclodextrins on surface and pore properties of soil clay minerals.

Jozefaciuk G, Muranyi A, Fenyvesi E.

Environ Sci Technol. 2001 Dec 15;35(24):4947-52.

PMID:
11775177
35.

Symmetrical stabilization of bound Ca2+ ions in a cooperative pair of EF-hands through hydrogen bonding of coordinating water molecules in calbindin D(9k).

Fast J, Håkansson M, Muranyi A, Gippert GP, Thulin E, Evenäs J, Svensson LA, Linse S.

Biochemistry. 2001 Aug 21;40(33):9887-95.

PMID:
11502182
36.

Myotonic dystrophy protein kinase phosphorylates the myosin phosphatase targeting subunit and inhibits myosin phosphatase activity.

Murányi A, Zhang R, Liu F, Hirano K, Ito M, Epstein HF, Hartshorne DJ.

FEBS Lett. 2001 Mar 30;493(2-3):80-4.

37.

Identification of the endogenous smooth muscle myosin phosphatase-associated kinase.

MacDonald JA, Borman MA, Murányi A, Somlyo AV, Hartshorne DJ, Haystead TA.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2419-24.

39.

1H, 15N and (13)C assignments and secondary structure of the EGF-like module pair 3-4 from vitamin K-dependent protein S.

Muranyi A, Evenäs J, Stenberg Y, Stenflo J, Drakenberg T.

FEBS Lett. 2000 Jun 16;475(2):135-8.

40.

Calcium-binding EGF-like modules in coagulation proteinases: function of the calcium ion in module interactions.

Stenflo J, Stenberg Y, Muranyi A.

Biochim Biophys Acta. 2000 Mar 7;1477(1-2):51-63. Review.

PMID:
10708848
41.

EGF-like module pair 3-4 in vitamin K-dependent protein S: modulation of calcium affinity of module 4 by module 3, and interaction with factor X.

Stenberg Y, Muranyi A, Steen C, Thulin E, Drakenberg T, Stenflo J.

J Mol Biol. 1999 Oct 29;293(3):653-65.

PMID:
10543957
42.

Protein phosphatase 2A plays a role in the suckling-induced changes in the responsiveness of pituitary mammotropes.

Murányi A, Gergely P, Fekete MI, Nagy GM.

Endocrinology. 1998 Nov;139(11):4590-7.

PMID:
9794470
43.

Solution structure of the N-terminal EGF-like domain from human factor VII.

Muranyi A, Finn BE, Gippert GP, Forsén S, Stenflo J, Drakenberg T.

Biochemistry. 1998 Jul 28;37(30):10605-15.

PMID:
9692950
44.

Identification and localization of myosin phosphatase in human platelets.

Murányi A, Erdodi F, Ito M, Gergely P, Hartshorne DJ.

Biochem J. 1998 Feb 15;330 ( Pt 1):225-31.

45.
46.

Quantitation of protein phosphatase 1 and 2A in extracts of the budding yeast and fission yeast.

Farkas I, Bakó E, Murányi A, Zeke T, Sipiczki M, Gergely P.

Int J Biochem Cell Biol. 1995 Aug;27(8):767-73.

PMID:
7584610
47.

Purification and characterization of three distinct types of protein phosphatase catalytic subunits in bovine platelets.

Erdödi F, Csortos C, Sparks L, Murányi A, Gergely P.

Arch Biochem Biophys. 1992 Nov 1;298(2):682-7.

PMID:
1329665
48.

Ueber die Wirkung der Morphin-Scopolaminnarkose auf die zentral und peripher bedingte Stoffwechselsteigerung.

ISSEKUTZ BV Jr, MURANYI A.

Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1948;205(4-5):406-14. Undetermined Language. No abstract available.

PMID:
18105523

Supplemental Content

Loading ...
Support Center